Stable rgd peptidomimetic composition

• US 20060246104A1
• Filed: 04/16/2004
• Published: 11/02/2006
• Est. Priority Date: 04/16/2003
• Status: Abandoned Application

• Current Assignee: Gholamreza Ehteshami, Stephen P. Massia
• Original Assignee: Gholamreza Ehteshami, Stephen P. Massia
• Inventors: Massia, Stephen P., Ehteshami, Gholamreza
• Application Number:
  US10/549,518
• Publication Number:
  US 20060246104A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61L 26/0047 Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: C07C 279/14 being further substituted by carboxyl groups
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00

Abstract

Disclosed herein are a chemical composition of 2-amino-6-[(2-amino-5{guanidine}pentanoyl)amino]hexanoic acid (AAGPAHA) and a method of making it. The pharmaceutical composition includes AAGPAHA and a pharmaceutical excipient. Such a composition is used in cell attachment in culture, as a coating of biomaterials and implants. The pharmaceutical composition of AAGPAHA can be used to treat cancer, thrombosis, osteoporosis, retinopathy, renal insufficiency and wounds.

Claims

1. The composition comprising 2-amino-6-[(2-amino-5{guanidine}pentanoyl)amino]hexanoic acid (AAGPAHA).

3. A method of encouraging cell attachment in cell culture, the method comprising

a. providing a cell culture substrate;

and

b. adding the compound of claim 1 to the cell culture substrate.

4. An implant resisting cellular interaction after implantation, the implant comprising

a. the implant;

and

b. a coating on the implant comprising the composition of claim 1.

5. A biomaterial suitable for implantation, the biomaterial capable of resisting cellular interaction after implantation, the biomaterial comprising

a. the biomaterial;

and

b. a coating on the biomaterial comprising the composition of claim 1.

2. A method of synthesizing an RGD peptidomimetic, the method comprising

a. combining equal equivalents of Fmoc-Arg(Pbf)-OH and N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluoruphosphate N-oxide (HATU) and dissolving in 0.5 M diisopropylethylamine in dimethylformamide (DMF);

b. preparing Boc-Lys (Fmoc)-resin by soaking in 20% piperidine and DMF;

c. combining the mixture of step a with the Boc-Lys-resin and allowing it to react; and

d. purifying the reaction mixture of c by washing with DMF and 20% piperidine.

6. A pharmaceutical composition comprising

a. AAGPAHA;

and

b. a pharmaceutical excipient.

7. A method of treating cancer in an individual suffering therefrom, the method comprising

a. providing the pharmaceutical composition of claim 6;

and

b. administering the pharmaceutical composition to the individual.

8. A method of treating thrombosis in an individual suffering therefrom, the method comprising

a. providing the pharmaceutical composition of claim 6;

and

b. administering the pharmaceutical composition to the individual.

9. A method of treating osteoporosis in an individual suffering therefrom, the met-hod comprising

a. providing the pharmaceutical composition of claim 6;

and

b. administering the pharmaceutical composition to the individual.

10. A method of treating retinopathy in an individual suffering therefrom, the method comprising

a. providing the pharmaceutical composition of claim 6;

and

b. administering the pharmaceutical composition to the individual.

11. A method of treating renal insufficiency in an individual suffering therefrom, the method comprising

a. providing the pharmaceutical composition of claim 6;

and

b. administering the pharmaceutical composition to the individual.

12. A method of treating wounds in an individual having at least one wound, the method comprising

a. providing the pharmaceutical composition of claim 6;

and

b. administering the pharmaceutical composition to the individual.